| Primary |
| Non-small Cell Lung Cancer |
21.2% |
| Breast Cancer |
17.3% |
| Product Used For Unknown Indication |
9.8% |
| Breast Cancer Metastatic |
8.1% |
| Lung Adenocarcinoma |
6.1% |
| Mesothelioma |
5.2% |
| Cervix Carcinoma Recurrent |
3.9% |
| Diffuse Large B-cell Lymphoma |
3.5% |
| Lung Cancer Metastatic |
3.5% |
| Chemotherapy |
3.3% |
| Lung Neoplasm Malignant |
2.9% |
| Hodgkin's Disease |
2.8% |
| Adenocarcinoma |
2.0% |
| Drug Use For Unknown Indication |
1.8% |
| Neoplasm Malignant |
1.8% |
| Pain |
1.8% |
| Her-2 Positive Breast Cancer |
1.5% |
| Squamous Cell Carcinoma |
1.3% |
| Disease Progression |
1.1% |
| Prophylaxis |
1.1% |
|
| Neutropenia |
13.0% |
| Interstitial Lung Disease |
10.6% |
| Neutropenic Sepsis |
9.8% |
| Vomiting |
9.8% |
| Pyrexia |
5.7% |
| Renal Failure Acute |
5.7% |
| Death |
4.9% |
| Pneumonia |
4.9% |
| Thrombocytopenia |
4.9% |
| White Blood Cell Count Decreased |
4.1% |
| Peritoneal Abscess |
3.3% |
| Renal Failure |
3.3% |
| Septic Shock |
3.3% |
| Anaemia |
2.4% |
| Febrile Neutropenia |
2.4% |
| Haematotoxicity |
2.4% |
| Nausea |
2.4% |
| Renal Disorder |
2.4% |
| Respiratory Failure |
2.4% |
| Toxicity To Various Agents |
2.4% |
|
| Secondary |
| Non-small Cell Lung Cancer |
25.9% |
| Breast Cancer |
20.0% |
| Breast Cancer Metastatic |
11.3% |
| Product Used For Unknown Indication |
10.0% |
| Drug Use For Unknown Indication |
5.4% |
| Hodgkin's Disease |
5.3% |
| Lung Neoplasm Malignant |
4.1% |
| Rhabdomyosarcoma |
3.1% |
| Sarcoma |
2.4% |
| Non-hodgkin's Lymphoma |
2.3% |
| Diffuse Large B-cell Lymphoma |
1.8% |
| Prophylaxis |
1.2% |
| Hypertension |
1.1% |
| Metastatic Neoplasm |
1.1% |
| Acute Myeloid Leukaemia |
0.9% |
| Acute Lymphocytic Leukaemia |
0.9% |
| Lymphoma |
0.9% |
| Her-2 Positive Breast Cancer |
0.8% |
| Sarcoma Metastatic |
0.8% |
| Invasive Ductal Breast Carcinoma |
0.7% |
|
| Vomiting |
17.2% |
| Neutropenia |
10.7% |
| Febrile Neutropenia |
6.1% |
| Pyrexia |
5.9% |
| Pulmonary Embolism |
5.5% |
| Pneumonia |
5.1% |
| Neutropenic Sepsis |
4.7% |
| Disease Progression |
4.3% |
| Rash |
4.3% |
| Pneumonitis |
4.1% |
| Stomatitis |
4.1% |
| Thrombocytopenia |
4.1% |
| Sepsis |
3.9% |
| Dyspnoea |
3.7% |
| Respiratory Failure |
3.3% |
| Dehydration |
2.9% |
| Constipation |
2.7% |
| Febrile Bone Marrow Aplasia |
2.5% |
| Interstitial Lung Disease |
2.5% |
| Nausea |
2.5% |
|
| Concomitant |
| Breast Cancer |
19.6% |
| Breast Cancer Metastatic |
17.5% |
| Product Used For Unknown Indication |
11.9% |
| Metastases To Bone |
11.8% |
| Drug Use For Unknown Indication |
8.4% |
| Non-small Cell Lung Cancer |
5.3% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Lung Neoplasm Malignant |
3.0% |
| Chemotherapy |
2.7% |
| Hodgkin's Disease |
2.6% |
| Pain |
2.3% |
| Neoplasm Malignant |
2.2% |
| Colon Cancer Metastatic |
1.4% |
| Metastatic Gastric Cancer |
1.4% |
| Antiemetic Supportive Care |
1.2% |
| Premedication |
1.2% |
| Burkitt's Lymphoma |
0.9% |
| Hypertension |
0.9% |
| Prophylaxis |
0.9% |
| Resorption Bone Increased |
0.9% |
|
| Disease Progression |
14.3% |
| Osteonecrosis |
12.0% |
| Osteonecrosis Of Jaw |
9.7% |
| Thrombocytopenia |
6.0% |
| Death |
5.1% |
| Wound Dehiscence |
5.1% |
| Tumour Marker Increased |
4.6% |
| Weight Decreased |
4.6% |
| Pyrexia |
3.7% |
| Tooth Extraction |
3.7% |
| Ulcer |
3.7% |
| Vomiting |
3.7% |
| Weight Increased |
3.7% |
| Metastases To Liver |
3.2% |
| Tooth Loss |
3.2% |
| Lung Neoplasm Malignant |
2.8% |
| Malignant Neoplasm Progression |
2.8% |
| Pneumothorax |
2.8% |
| Pulmonary Oedema |
2.8% |
| Rash |
2.8% |
|
| Interacting |
| Hiv Infection |
28.6% |
| Kaposi's Sarcoma |
28.6% |
| Depression |
14.3% |
| Drug Use For Unknown Indication |
14.3% |
| Oral Disorder |
14.3% |
|
|
